Literature DB >> 16509862

Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors.

Tram T Tran1, Chanikarn Changsri, C R Shackleton, Fred F Poordad, Nicholas N Nissen, Steven Colquhoun, Stephen A Geller, John M Vierling, Paul Martin.   

Abstract

OBJECTIVE: With the continued shortage of deceased donor grafts, living donor liver transplantation has become an option for adult liver transplant candidates. In the non-transplant setting, liver biopsy is typically carried out to evaluate clinical or biochemical hepatic dysfunction. In living donor liver transplantation, assessment of histological abnormalities that are undetectable by serological, biochemical and radiological methods might play an important role in donor and recipient outcome.
METHODS: Seventy consecutive liver biopsies carried out as part of our evaluation of potential donor candidates for adult-to-adult or adult-to-child living donor liver transplants were analyzed.
RESULTS: Of the 70 potential donor candidates who underwent liver biopsy for evaluation for living donor liver transplantation, 67% had an unexpected abnormality, of which steatosis was the most common abnormality (38.5%). A variety of other histopathological abnormalities were found including granulomas of unknown etiology (7%), chronic hepatitis (6%) and a microabscess. None of the histological abnormalities had been suspected despite extensive clinical, serological or radiological investigation.
CONCLUSIONS: Among the 70 potential donor candidates for living donor liver transplantation, 34% had unremarkable liver biopsies. The most common abnormality was steatosis (38.5%). These findings suggest that all potential candidates for living donor liver transplants should undergo screening liver biopsies. The precise significance of these changes remains to be determined, including which of these changes are contraindications to liver transplantation. These findings may also have implications in the non-transplant setting as changes ascribed to specific etiologies for liver disease might include changes occurring in apparently healthy individuals.

Entities:  

Mesh:

Year:  2006        PMID: 16509862     DOI: 10.1111/j.1440-1746.2005.03968.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  12 in total

1.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.

Authors:  Jody Dushay; Patricia C Chui; Gosala S Gopalakrishnan; Marta Varela-Rey; Meghan Crawley; Ffolliott M Fisher; Michael K Badman; Maria L Martinez-Chantar; Eleftheria Maratos-Flier
Journal:  Gastroenterology       Date:  2010-05-05       Impact factor: 22.682

2.  CT indices for the diagnosis of hepatic steatosis using non-enhanced CT images: development and validation of diagnostic cut-off values in a large cohort with pathological reference standard.

Authors:  Jieun Byun; Seung Soo Lee; Yu Sub Sung; Youngbin Shin; Jessica Yun; Ho Sung Kim; Eun Sil Yu; Sung-Gyu Lee; Moon-Gyu Lee
Journal:  Eur Radiol       Date:  2018-12-19       Impact factor: 5.315

3.  Is there any progress in the treatment of non-alcoholic fatty liver disease?

Authors:  Emmanuel A Tsochatzis; George V Papatheodoridis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-02-06

4.  Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study.

Authors:  Yuichiro Eguchi; Hideyuki Hyogo; Masafumi Ono; Toshihiko Mizuta; Naofumi Ono; Kazuma Fujimoto; Kazuaki Chayama; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2012-02-11       Impact factor: 7.527

5.  Impact of living donor liver with steatosis and idiopathic portal inflammation on clinical outcomes in pediatric liver transplantation: Beijing experience.

Authors:  Yafei He; Xinyan Zhao; Jimin Liu; Qian Zhang; Liwei Liu; Wei Qu; Ying Liu; Zhigui Zeng; Haiming Zhang; Jidong Jia; Liying Sun; Lin Wei; Zhijun Zhu
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

Review 6.  The genetics of NAFLD.

Authors:  Quentin M Anstee; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-24       Impact factor: 46.802

Review 7.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

Authors:  Quentin M Anstee; Giovanni Targher; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-19       Impact factor: 46.802

Review 8.  Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations.

Authors:  Zaki A Sherif; Armana Saeed; Shima Ghavimi; Seyed-Mehdi Nouraie; Adeyinka O Laiyemo; Hassan Brim; Hassan Ashktorab
Journal:  Dig Dis Sci       Date:  2016-04-01       Impact factor: 3.199

9.  Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan.

Authors:  Kazuya Okushin; Yu Takahashi; Nobutake Yamamichi; Takeshi Shimamoto; Kenichiro Enooku; Hidetaka Fujinaga; Takeya Tsutsumi; Yoshizumi Shintani; Yoshiki Sakaguchi; Satoshi Ono; Shinya Kodashima; Mitsuhiro Fujishiro; Kyoji Moriya; Hiroshi Yotsuyanagi; Toru Mitsushima; Kazuhiko Koike
Journal:  BMC Gastroenterol       Date:  2015-02-19       Impact factor: 3.067

Review 10.  From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome?

Authors:  Mihai Alexandru Munteanu; Petru Adrian Mircea
Journal:  Clujul Med       Date:  2014-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.